The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Novel APC-like properties of human NK cells directly regulate T cell activation
Hanna, J., Gonen-Gross, T., Fitchett, J., Rowe, T., Daniels, M., Arnon, T. I., Gazit, R., Joseph, A., Schjetne, K. W., Steinle, A., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22787 · Cited by 162
RetractedJemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Stress, depression, the immune system, and cancer
Reiche, E. M. V., Nunes, S. O. V., & Morimoto, H. K. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01597-9 · Cited by 1,364
Scagliotti, G. V., De Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889
Prospects for the use of NK cells in immunotherapy of human cancer
Ljunggren, H.-G., & Malmberg, K.-J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2073 · Cited by 543
Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H.-I., Antonia, S., Altiok, S., Celis, E., & Gabrilovich, D. I. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40269 · Cited by 460
Cooper, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.012 · Cited by 434
D'Addario, G., Pintilie, M., Leighl, N. B., Feld, R., Cerny, T., & Shepherd, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.045 · Cited by 363
Interleukin-2, Interleukin-15, and Their Roles in Human Natural Killer Cells
Becknell, B., & Caligiuri, M. A. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(04)86006-1 · Cited by 325
Effector and regulatory events during natural killer–dendritic cell interactions
Moretta, L., Ferlazzo, G., Bottino, C., Vitale, M., Pende, D., Mingari, M. C., & Moretta, A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00450.x · Cited by 304
Berg, M., Lundqvist, A., McCoy, P., Samsel, L., Fan, Y., Tawab, A., & Childs, R. (2009) · Cytotherapy · doi:10.1080/14653240902807034 · Cited by 304
NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity
Albertsson, P. A., Basse, P. H., Hokland, M., Goldfarb, R. H., Nagelkerke, J. F., Nannmark, U., & Kuppen, P. J. K. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.09.007 · Cited by 226
Cancer Vaccines: Moving Beyond Current Paradigms
Schlom, J., Arlen, P. M., & Gulley, J. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0588 · Cited by 207
NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation
Ruggeri, L., Mancusi, A., Burchielli, E., Capanni, M., Carotti, A., Aloisi, T., Aversa, F., Martelli, M. F., & Velardi, A. (2008) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2007.06.029 · Cited by 161
Krebs, P., Barnes, M., Lampe, K., Whitley, K., Bahjat, K., Beutler, B., Janssen, E., & Hoebe, K. (2009) · Blood · doi:10.1182/blood-2009-01-201467 · Cited by 160
Baxevanis, C. N., Perez, S. A., & Papamichail, M. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0576-4 · Cited by 156
Self-citationExploitation of alloreactive NK cells in adoptive immunotherapy of cancer.
Ruggeri, L., Mancusi, A., Capanni, M., Martelli, M., & Velardi, A. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.01.007 · Cited by 128
Human NK cells: from HLA class I‐specific killer Ig‐like receptors to the therapy of acute leukemias
Moretta, A., Locatelli, F., & Moretta, L. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00651.x · Cited by 128
Gill, S. I., Olson, J. A., & Negrin, R. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.01.019 · Cited by 104
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg, K., Bryceson, Y., Carlsten, M., Andersson, S., Björklund, A., Björkström, N., Baumann, B. C., Fauriat, C., Alici, E., Dilber, M., et al. (2008) · Cancer Immunology and Immunotherapy · doi:10.1007/s00262-008-0492-7 · Cited by 92
Killers and beyond: NK‐cell‐mediated control of immune responses
Andoniou, C. E., Coudert, J. D., & Degli‐Esposti, M. A. (2008) · European Journal of Immunology · doi:10.1002/eji.200838882 · Cited by 86
de Santis, D., Bishara, A., Witt, C., Nagler, A., Brautbar, C., Slavin, S., & Christiansen, F. (2005) · Tissue Antigens · doi:10.1111/j.1399-0039.2005.00396.x · Cited by 82
Combined modality immunotherapy and chemotherapy: a new perspective
Ramakrishnan, R., Antonia, S. J., & Gabrilovich, D. I. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0531-4 · Cited by 74
Re, F., Staudacher, C., Zamai, L., Vecchio, V., & Bregni, M. (2006) · Cancer · doi:10.1002/cncr.22002 · Cited by 69
First- and second-line therapy for advanced nonsmall cell lung cancer
Jp, S., & Moro‐Sibilot, D. (2009) · European Respiratory Journal · doi:10.1183/09031936.00132008 · Cited by 68
Links between innate and cognate tumor immunity
Ghiringhelli, F., Apétoh, L., Housseau, F., Kroemer, G., & Zitvogel, L. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.02.003 · Cited by 61
Perez, S. A., Mahaira, L. G., Demirtzoglou, F. J., Sotiropoulou, P. A., Ioannidis, P., Iliopoulou, E. G., Gritzapis, A. D., Sotiriadou, N. N., Baxevanis, C. N., & Papamichail, M. (2005) · Blood · doi:10.1182/blood-2004-08-3232 · Cited by 55
Self-citationKosmidis, P., Kalofonos, H. P., Christodoulou, C., Syrigos, K. N., Makatsoris, T., Skarlos, D.-V., Bakogiannis, C., Nicolaides, C., Bafaloukos, D. I., Bamias, A., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm430 · Cited by 52
Zhang, T., & Herlyn, D. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0598-y · Cited by 48
Natural Killer Cell Alloreactivity in Haploidentical Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Mancusi, A., Perruccio, K., Burchielli, E., Martelli, M. F., & Velardi, A. (2005) · International Journal of Hematology · doi:10.1532/ijh97.04172 · Cited by 36
Natural killer cell‐mediated lysis of freshly isolated human tumor cells
Carlsten, M., Malmberg, K., & Ljunggren, H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24082 · Cited by 31
Slavin, S., Ackerstein, A., Or, R., Shapira, M. Y., Gesundheit, B., Askenasy, N., & Morecki, S. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0878-1 · Cited by 19
Exploiting beneficial alloreactive T cells
Barber, L. D., & Madrigal, J. A. (2006) · Vox Sanguinis · doi:10.1111/j.1423-0410.2006.00775.x · Cited by 13
Cited by
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
NK cell-based cancer immunotherapy: from basic biology to clinical development
Liu, S., Galat, V., Galat4, Y., Lee, Y. K. A., Wainwright, D., & Wu, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01014-w · Cited by 689
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Metadata
- Authors
- Iliopoulou, E. G., Kountourakis, P., Karamouzis, M. V., Doufexis, D., Ardavanis, A., Baxevanis, C. N., Rigatos, G., Papamichail, M., & Perez, S. A.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2010-08-12
- Volume
- 59
- Issue
- 12
- Pages
- 1781-1789
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2035313744
- Cited by
- 277
- References
- 36
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.